news

New way to target treatment-resistant cancers identified

A new mechanism by which cancer cells become resistant to chemotherapy has been found which could lead to a new target for drugs.

A new way cancer becomes resistant to chemotherapy has been discovered by researchers from Germany and Imperial College London, suggesting a new target for oncologic drugs.

Chemotherapy kills cancer cells by inducing ‘cell death’, one form of which (ferroptosis – iron-dependent cell death) is caused by the degradation of lipids that make up the cell membrane.

Now, scientists have discovered a new mechanism by which cancer cells become resistant to ferroptosis. Many aggressive and drug-resistant cancers are vulnerable to ferroptosis but they can also use particular mechanisms to block it.

The new study identified a new target for drugs that suppress the novel mechanism, allowing ferroptosis cell death to take hold in susceptible cancer cells.

“Discovering a completely new way cells gain resistance will allow us to design drugs that target this mechanism,” said Professor Ed Tate at Imperial. 

Discovering a completely new way cells gain resistance will allow us to design drugs that target this mechanism”

Ferroptosis relies on oxidation on lipids in the cell membrane – the stripping of electrons from these lipids, causing them to degrade. It was already known that one molecule, called glutathione peroxidase 4 (GPX4), reverses this process, acting as an antioxidant. However, the researchers discovered a different molecule called FSP1 that also acts as a lipid antioxidant, rescuing cancer cells from ferroptosis cell death even when they are starved of GPX4.

The team also found several potential ways to target it with drugs and therefore reduce resistance.

To work, FSP1 needs the help of an enzyme called N-myristoyltransferase, or NMT. Previously, the team at Imperial developed drug leads for suppressing the activity of NMT in order to block infection by the common cold virus.

“As therapy-resistant tumours gain resistance to ferroptosis, treatments that promote ferroptosis based on inhibition of FSP1, GPX4, NMT or a combination of all three, have great potential for translation into future clinical applications,” added Andrea Goya Grocin from Imperial. 

The study was published in Nature.

Send this to a friend